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Adenovirus Vector Expressing Stx1/Stx2-Neutralizing Agent Protects
Piglets Infected with Escherichia coli O157:H7 against Fatal Systemic
Intoxication
Abhineet S. Sheoran,a Igor P. Dmitriev,b Elena A. Kashentseva,b Ocean Cohen,a Jean Mukherjee,a Michelle Debatis,a
Jonathan Shearer,a Jacqueline M. Tremblay,a Gillian Beamer,a David T. Curiel,b Charles B. Shoemaker,a Saul Tziporia
Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USAa; Department of
Radiation Oncology, Washington University, St. Louis, Missouri, USAb
Hemolytic-uremic syndrome (HUS), caused by Shiga toxin (Stx)-producing Escherichia coli (STEC), remains untreatable. Pro-
duction of humanmonoclonal antibodies against Stx, which are highly effective in preventing Stx sequelae in animal models, is
languishing due to cost and logistics. We reported previously that the production and evaluation of a camelid heavy-chain-only
VH domain (VHH)-based neutralizing agent (VNA) targeting Stx1 and Stx2 (VNA-Stx) protected mice from Stx1 and Stx2 intoxi-
cation. Here we report that a single intramuscular (i.m.) injection of a nonreplicating adenovirus (Ad) vector carrying a secre-
tory transgene of VNA-Stx (Ad/VNA-Stx) protected mice challenged with Stx2 and protected gnotobiotic piglets infected with
STEC from fatal systemic intoxication. One i.m. dose of Ad/VNA-Stx prevented fatal central nervous system (CNS) symptoms in
9 of 10 animals when it was given to piglets 24 h after bacterial challenge and in 5 of 9 animals when it was given 48 h after bacte-
rial challenge, just prior to the onset of CNS symptoms. All 6 placebo animals died or were euthanized with severe CNS symp-
toms. Ad/VNA-Stx treatment had no impact on diarrhea. In conclusion, Ad/VNA-Stx treatment is effective in protecting piglets
from fatal Stx2-mediated CNS complications following STEC challenge. With a low production cost and further development,
this could presumably be an effective treatment for patients with HUS and/or individuals at high risk of developing HUS due to
exposure to STEC.
Infectionwith Shiga toxin (Stx)-producing Escherichia coli (STEC)is the most significant cause of hemolytic-uremic syndrome
(HUS), the leading cause of acute renal failure in children (1–4)
and in some adults. Of the two antigenically distinct toxins, Stx1
and Stx2, Stx2 ismore firmly linkedwith the development ofHUS,
since STEC strains producing this toxin are more frequently asso-
ciated with HUS than strains that produce both Stx1 and Stx2,
while Stx1 alone has rarely been associated with HUS (5–7). Stx1
and Stx2 are similar in basic structure (8), binding specificity (8),
and mode of action (9, 10). Both toxins consist of an A-subunit
monomer and aB-subunit pentamer (8, 11, 12). The pentameric B
subunit binds to its cell surface receptor, CD77, also called globot-
riaosyl ceramide (Gb3; Gal1-4 Gal1-4 glucosyl ceramide) (13,
14). This binding triggers endocytosis of the holotoxin, mainly
through clathrin-coated pits (15). Internalization of the catalyti-
cally activeA subunit, delivered to the cytosol via retrograde trans-
port, causes the shutdown of protein synthesis and leads to cell
death (9, 10). In addition to blocking protein synthesis, a long-
term effect of the toxin in several types of cells is the induction of
apoptosis (16).
We previously reported the production of humanmonoclonal
antibodies (HuMAbs) against Stx1 and Stx2 and their evaluation
in animalmodels for efficacy against systemic toxin challenge (17–
19) or oral STEC infection (17, 19–21). Clinical evaluation of
these monoclonal antibodies has been slow and is still pending,
due largely to the logistics and cost.We also reported the use of an
alternative antitoxin strategy that employs “VHH-based neutral-
izing agents” (VNAs) consisting of linked 14-kDa camelid heavy-
chain-only VH domains (VHHs), produced as heteromultimers,
that bind and neutralize toxin targets (22, 23). Linking VHHs to
form VNAs results in agents with much greater therapeutic effi-
cacy in preventing intoxication in animals due to exposure to Stx1
and Stx2 (23), botulinum neurotoxin (22), ricin (24), or Clostrid-
ium difficile toxins TcdA and TcdB (25) than equivalent pools of
the VHH components. VNAs also contain several copies of an
epitopic tag recognized by an anti-tag MAb. Coadministration of
the anti-tagMAb, called the effector antibody (efAb), can enhance
the therapeutic efficacy of VNA in some intoxicationmodels (22–
25), probably by promoting toxin clearance through the liver (26).
Inclusion of an albumin-binding peptide (ABP) substantially pro-
longed the functional half-life of VNA in serum, from 1 to 2 h to
more than a day (27).
VNA antitoxins offer the potential for genetic delivery using
vehicles that lead to the expression of antitoxin protein by pa-
tients. Awide variety of genetic delivery vehicles have already been
developed, including direct administration of DNA and RNA, re-
combinant adenovirus (Ad) (28–30), and adeno-associated virus
(AAV) (31, 32). Furthermore, gene delivery vehicles can effec-
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tively promote in vivo expression of a range of antibody species for
passive immunotherapy (28, 29, 33, 34).We have shown that gene
therapy with an Ad expressing a VNA that neutralizes botulinum
neurotoxin serotype A (VNA-BoNT/A) resulted in sustained high
levels of VNA-BoNTA in serum that protected mice from
BoNT/A challenge for several months (27).
In this study, we report the use of a recombinant, replication-
incompetent human Ad serotype 5 (Ad5) vector that promotes de
novo secretion of antitoxin VNAs into the circulation. The Ad/
VNA-Stx vector produces a potent anti-Stx VNA, a VHH hetero-
trimer (A9/A5/G1 [23]) that recognizes both Stx1 and Stx2. Here
we demonstrate that a single administration of Ad/VNA-Stx pro-
tects mice against Stx2 intoxication following parenteral toxin
challenge and protects piglets against fatal systemic intoxication
when given 24 h after oral STEC infection.
MATERIALS AND METHODS
Ethics statement. The mouse and piglet studies described in this report
were carried out in strict accordancewith theNational Institutes ofHealth
guidelines for the ethical treatment of animals and were approved by the
Institutional Animal Care and Use Committee of Tufts University.
Bacteria and toxin. Enterohemorrhagic E. coli (EHEC) O157:H7
strain 86-24, which produces Stx2, was isolated in 1986 from a patient
with hemorrhagic colitis in Seattle, WA (35). Stx2, purified as described
previously (36), was obtained from the Phoenix Laboratory (Tufts Uni-
versity–NEMCMicrobial Products and Services Facility). Before use, the
toxin was passed through a Polyacrylamide 6000 Desalting column
(Thermo Scientific, IL) in order to suspend it in phosphate-buffered sa-
line (PBS) (pH 7.2). The toxin was quantified by UV spectrophotometry
(ND-1000 spectrophotometer; NanoDrop), aliquoted, and stored at
20°C.
Adenovirus vector construction and preparation. The recombinant
replication-incompetent Ad5-based vector was generated essentially as
described elsewhere (37). Briefly, the genome of the Ad/VNA-Stx vector
was generated using the pShCMV-JHQ9 shuttle plasmid, which was con-
structed by subcloning DNA encoding VNA-Stx, a VHH heterotrimer
(A9/A5/G1 [23]) recognizing both Stx1 and Stx2, with a carboxyl-termi-
nal ABP under the control of a cytomegalovirus (CMV) promoter within
plasmid pAdTrack (38) while replacing the CMV-driven green fluores-
cent protein (GFP) gene. The pShCMV-JHQ9 plasmid was linearized
with BstZ17I and was employed for homologous recombination with the
pAdEasy-1 plasmid (38) using E. coli BJ5183-AD-1 cells as recommended
by themanufacturer (Agilent Technologies, Inc., Santa Clara, CA) to gen-
erate the pAd/VNA-Stx rescue plasmid containing the viral genome. The
resultant pAd/VNA-Stx plasmid, which was validated by PCR, restriction
analysis, and partial sequencing, was first digested with PacI to release the
inverted terminal repeats of the viral genomic DNA and then transfected
into 293 cells (39) to rescue the replication-incompetent Ad/VNA-Stx
vector. The newly rescued Ad vector was propagated on 911 cells (40),
purified by centrifugation on CsCl gradients according to the standard
protocol, and dialyzed against PBS (8mMNa2HPO4, 2mMKH2PO4 [pH
7.4], 137 mM NaCl, 2.7 mM KCl) containing 10% glycerol. The titers of
physical virus particles (vp) were determined by the methods of Maizel et
al. (41).
Mouse toxicitymodel.Themouse toxicitymodel (19, 20) was used to
determine the efficacy of Ad/VNA-Stx in protectingmice against a paren-
teral challenge with a lethal Stx2 dose. Two groups of 10 4-week-old
female Swiss Webster mice (Charles River Laboratories, Inc.) were in-
jected intraperitoneally (i.p.) with 60 ng (2.5 100% lethal doses [LD100])
of Stx2.One of the two groupswas injected i.p. with 1 1010 Ad/VNA-Stx
vp in 100 l PBS/mouse 4 h prior to administration of the toxin, and
another group was injected with PBS at this time. Mice were monitored
for illness and death 4 or more times daily for 1 week. Mice that were
severely ill were humanely euthanized. Similarly, surviving animals were
humanely euthanized 1 week after Stx2 challenge. Blood was collected for
the measurement of serum VNA-Stx concentrations before euthanasia.
Gnotobiotic pigletmodel of STEC infection.The Ad/VNA-Stx treat-
ment was further evaluated in the gnotobiotic piglet infection model of
STEC using E. coli strain 86-24 (17, 20). A total of 35 piglets were used to
determine the protective efficacy of the Ad/VNA-Stx treatment, given
intramuscularly (i.m.), either 18 h before (5 piglets treated, 5 given a
placebo) or 24 h (10 treated, 6 given a placebo) or 48 h (9 treated) after
bacterial challenge with1010 CFU of 86-24. This high inoculum usually
induces neurological signs and lesions associatedwith Stx2 activity in 95%
of control piglets within 48 to 96 h postinfection (20, 42). The placebo
group received either PBS or anAd5-based vector expressingVNA against
botulinum neurotoxin serotype A (Ad/VNA-BoNTA) (27) or C. difficile
toxins TcdA and TcdB (Ad/VNA-Tcd) (unpublished data). Piglets were
monitored4 times daily for diarrhea, dehydration, and central nervous
system (CNS) symptoms, which included ataxia, paresis, head pressing,
paddling, convulsions, and opisthotonos. Animals with severe CNS
symptoms, as well as surviving animals 7 to 12 days after the bacterial
challenge, were humanely euthanized. Brain tissue (cerebral cortex and
cerebellum) and gut sections were fixed in formalin and were processed
for histology, and blood was collected for the measurement of serum
antibody concentrations.
Another group of 4 control piglets was intramuscularly administered
1  1011 Ad/VNA-Stx vp/kg of body weight 48 h after birth but was not
challenged with STEC. These piglets were bled every day for 7 days in
order to determine the kinetics of serum VNA-Stx.
Capture ELISAs to measure serum VNA levels. MaxiSorp C96 im-
munoplates (Nunc) or 96-well tissue culture plates (Corning)were coated
overnight with 100 l/well of 1 g/ml Stx2 (Phoenix Laboratory, Tufts
University, Boston, MA). Affinity-purified recombinant VNA-Stx was
used as the standard in every plate to estimate VNA-Stx levels in piglet/
mouse sera. This standard was “spiked” into normal mouse/piglet serum
at 80 nM (4 g/ml). Enzyme-linked immunosorbent assays (ELISAs)
were performed in which spiked serum or test sera were applied to a well
at a 1:10 dilution, followed by seven 1:5 serial dilutions. VNAbound to the
coated Stx2 was detected with a horseradish peroxidase (HRP)-conju-
gated anti-E-tagMAb (GEHealthcare). By use of the linear portion of the
VNA-Stx standard-curve plot, the VNA-Stx content of each piglet/mouse
test serum sample was determined and was expressed as micrograms of
VNA-Stx per milliliter. Typically, signals 2-fold above background were
achieved in dilutions of the VNA-Stx standard down to about 30 pM (1.5
ng/ml). Thus, all assays measuring levels below 30 pMwere considered to
have results “below the detection limit.” VNA-BoNTA and VNA-Tcd
levels in serum were determined in the same manner, by employing the
target of the control VNA in place of Stx2 in the ELISA.
Statistical analysis. The grouped survival data were analyzed by ap-
plying a Kaplan-Meier log rank test using SigmaPlot (version 13.0; Systat
Software, Inc.). Resulting P values of0.05 were considered significant.
RESULTS
Efficacy of Ad/VNA-Stx treatment in themouse toxicity model.
A replication-defective Ad5 vector was engineered to promote
mammalian-cell secretion of the recombinant heterotrimeric
VHH-based neutralizing agent (VNA) that potently neutralizes
both Shiga toxins, Stx1 and Stx2 (23) (VNA-Stx). The resulting
vector, called Ad/VNA-Stx, was administered i.p. to groups of
mice (1010 vp/mouse) 4 h prior to intoxication with Stx2 (60 ng/
mouse;2.5 LD100). All mice given Ad/VNA-Stx survived, while
all placebo (PBS)-treated mice succumbed to Stx2 toxicity within
2 to 3 days (Table 1). The difference in survival time between the 2
groups was statistically significant (P 0.001). All the mice in the
Ad/VNA-Stx-treated group gained weight following the toxin
challenge (mean weight gain, 1.33 g on day 2 [Fig. 1]). In contrast,
all mice in the placebo group lost weight (mean weight loss, 1.92 g
Stx-Neutralizing Agent Protects Piglets
January 2015 Volume 83 Number 1 iai.asm.org 287Infection and Immunity
 o
n
 January 10, 2015 by W
ashington University in St. Louis
http://iai.asm
.org/
D
ow
nloaded from
 
on day 2 [Fig. 1]). Serum VNA-Stx concentrations in mice, mea-
sured at the end of the experimental period (1 week after Ad/
VNA-Stx treatment), ranged from0.5 to 6.0g/ml, with ameanof
2.55 g/ml (Table 1).
Efficacy of Ad/VNA-Stx treatment in the piglet diarrhea
model of oral STEC infection.Piglets receivedAd/VNA-Stx treat-
ment either 18 h before (Table 2) or 24 h or 48 h after (Table 3)
bacterial infection. Almost all piglets in all groups, irrespective of
the time of Ad/VNA-Stx treatment, developed diarrhea within 20
to 55 h (the majority within 42 to 48 h) after the challenge. The
Ad/VNA-Stx treatments were intramuscular (i.m.) and were ad-
ministered before the onset of systemic complications/CNS symp-
toms, which tended to develop 48 h after the oral STEC chal-
lenge.
Treatment with 1  1012 vp of Ad/VNA-Stx per kg of body
weight administered 18 h before oral STEC challenge significantly
protected all piglets from fatal systemic intoxication, whereas all
piglets in the placebo (PBS) group succumbed to Stx2-associated
CNS symptoms after the oral STEC challenge (P 0.001) (Table
2). Serum VNA-Stx concentrations ranged from 0.025 to 0.1 g/
ml, with a mean of 0.05 g/ml (Table 2).
Table 3 summarizes piglet survival following treatment with
either of two doses of Ad/VNA-Stx (1 1011 or 1 1012 vp/kg of
body weight) administered 24 h or 48 h after oral STEC infection.
All six pigs in the group receiving the 1  1011-vp/kg dose 24 h
after infection were fully and significantly protected (P 	 0.009)
against systemic intoxication. Similarly, the 1  1012-vp/kg dose
given 24 h postinfection significantly protected piglets (3 of 4 pig-
lets protected; P 	 0.04). Mean serum VNA-Stx concentrations
were 0.7 g/ml for pigs given the 1012-vp/kg dose and 0.08 g/ml
for pigs given 1011 vp/kg. The one Ad/VNA-Stx-treated pig that
succumbed survived for 5 days after infection. In contrast, in pigs
treated 48 h after infection, either dose of Ad/VNA-Stx protected
only about 50% (5/9) of piglets fromSTEC sequelae and death; the
survival of piglets in these groups was not significantly different
from that of placebo-treated piglets. Serum VNA-Stx concentra-
tions averaged 0.23 g/ml in the group receiving the 1012-vp/kg
dose and 0.15 g/ml in the group receiving 1011 vp/kg. All piglets
in the placebo (Ad/VNA-BoNTA or Ad/VNA-Tcd) group suc-
cumbed after challenge, with amean survival time of 3.5 days. The
mean concentrations ofVNA-BoNTA (in the group receiving 1012
vp of Ad/VNA-BoNTA/kg) and VNA-Tcd (in the group receiving
1011 vp of Ad/VNA-Tcd/kg) in serum were 3.75 g/ml and 0.02
g/ml, respectively.
We also studied the kinetics of VNA-Stx in serum after the
administration of Ad/VNA-Stx to 4 piglets that were not chal-
lenged with STEC in order to determine VNA-Stx levels in the
absence of the toxin over 7 days. The mean serum VNA-Stx con-
centrations for these pigs on days 1, 2, 3, 4, 5, 6, and 7 were 11.3,
16.7, 41.3, 65.0, 10.0, 10.0, and 10.0 ng/ml, respectively. VNA-Stx
was clearly detectable within a day after Ad/VNA-Stx administra-
tion, peaked on day 4, and remained detectable for at least several
more days.
Clinical observations. Untreated piglets challenged orally with
STEC typically develop profound gastrointestinal (GI) tract symp-
toms within 2 days, which include diarrhea, anorexia, depression,
dehydration, and moderate but rapid loss of body weight. Dehydra-
tion often requires fluid therapy, but the piglets in this study were
mildly dehydrated anddid not needfluid therapy. The appearance of
GI tract symptoms was highly variable. Half of the piglets listed in
Table 2, which received Ad/VNA-Stx or a placebo at 18 h before
bacterial challenge, developed GI tract symptoms within 20 to 23 h,
and another half developed these symptomswithin 44 h of infection.
Five of the 6 placebo-treated piglets listed in Table 3 developed diar-
rhea within 44 to 50 h of infection, and 1 developed diarrhea within
76 h after infection. Fourteen of the 19 Ad/VNA-Stx-treated piglets
TABLE 1 Survival of mice given an Stx2-neutralizing VNA treatment or
a placebo intraperitoneally 4 h before challenge with Stx2
Treatmenta
Dose
(vp/mouse)
No. of
surviving
mice
(% survival)b
Mean time
(days) to
death/
euthanasia
(
 SD)c
Mean serum
VNA concn
(g/ml)
(range)d
Ad/VNA-Stx 1 1010 10 (100) 7.0 (
0.0) A 2.55 (0.5–6.0)
Placebo PBS 0 (0) 2.4 (
0.5) B
a There were 10 mice in each group. Mice in the Ad/VNA-Stx group were given an
Stx2-neutralizing VNA treatment intraperitoneally 4 h before Stx2 challenge. Mice in
the placebo group received PBS only.
b Mice in the placebo group either died overnight or were euthanized due to severe
illness. All mice in the Ad/VNA-Stx group survived and were euthanized after 7 days.
c Different capital letters following survival times indicate statistically significant
differences (P 0.001) between those treatment groups.
d Estimated concentration of VNA in mouse serum at the time of euthanasia.
FIG 1 Change in body weight. The group that received Stx2 only consistently
lost weight and succumbed to Stx2 toxicity within 2 to 3 days of toxin admin-
istration. In contrast, the group that received Ad/VNA-Stx treatment 4 h prior
to toxin administration (Stx2Ad/VNA-Stx) consistently gained weight, and
all mice in this group survived.
TABLE 2 Survival of piglets given either a placebo or an Stx2-
neutralizing VNA treatment intramuscularly 18 h before oral challenge
with 1 1010 CFU of STEC 86-24
Treatmenta
Dose
(vp/kg)
No. of
surviving
piglets
(% survival)b
Mean time
(days) to
death/
euthanasia
(
 SD)c
Mean serum
VNA concn
(g/ml)
(range)d
Ad/VNA-Stx 1 1012 5 (100) 12 (
0.0) A 0.05 (0.025–0.1)
Placebo PBS 0 (0) 5.0 (
2.0) B
a There were 5 piglets per group.
b Piglets in the placebo group either died overnight or were euthanized due to severe
illness.
c All piglets in the Ad/VNA-Stx group were euthanized after 12 days. Different capital
letters following survival times indicate statistically significant differences (P 0.001)
between those treatment groups.
d Estimated concentration of VNA in piglet serum at the time of euthanasia.
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survived (Table 3); themajority of them (12 piglets) developed diar-
rhea within 44 to 48 h of infection, and 2 developed diarrhea within
65 h after infection. The 5 Ad/VNA-Stx-treated piglets that did not
survive (Table 3) developeddiarrheawithin 44 to 48h after infection.
As expected, while parenteral administration of Ad/VNA-Stx had a
major impact on animal survival, it had no effect on the GI tract
symptoms. Typically, all piglets challenged with STEC develop diar-
rhea and other GI tract symptoms due to an intimate attachment of
bacteria to the mucosal surfaces of the terminal ileum and the entire
largebowel, including the colonandcecum.Thenature, distribution,
and extent of the mucosal lesions in gnotobiotic piglets induced by
STEC strain 86-24were consistentwith those described in the past by
us (20, 43–45) and others (46).
DISCUSSION
This project builds on earlier work that describes in detail the
VNA technology developed in this lab (22, 23), specifically, a sin-
gle VNA, now called VNA-Stx, that targets both Stx1 and Stx2 for
potent neutralization (23). This VNA, consisting of three different
Stx-binding VHHs linked into a heterotrimer, fully protected
mice from lethal doses of Stx1 or Stx2 when coadministered with
an effector antibody to promote toxin clearance. In this study, we
show that de novo expression of a VNA-Stx transgene following
treatment with a recombinant Ad vector can lead to protection
from Stx2 exposure in mice and from the fatal systemic intoxica-
tion caused by STEC infection in piglets.
The gnotobiotic piglet has been used extensively over the last 2
decades by several investigators, including us (17, 20, 21), to study
the sequence of events leading to diarrhea and systemic intoxica-
tion due to Stx uptake from severely damaged colonic mucosae.
STEC infections can cause severe kidney injury, at least temporar-
ily, in subsets of infected children and adults. Although neurolog-
ical complications are less common in human patients, systemic
complications manifest largely in the form of fatal CNS vascular
injury in piglets. Therefore, we use fatal CNSmanifestations as the
endpoint. In children, the prodromal period is 3 to 7 days between
the onset of diarrhea due to STEC and HUS, while in piglets, this
period is typically 2 to 4 days (17, 20, 21).
While acute STEC diarrhea tends to be transient, with rapid
recovery, in humans, a few infected individuals (especially young
children and the elderly) go on to develop serious, even fatal con-
sequences, such as hemolytic anemia, thrombocytopenia, acute
kidney failure, and sometimes neurological symptoms (7). In
some survivors of HUS, long-term kidney damage may require
dialysis. Therefore, there is a critical need for an effective treat-
ment that can prevent the sequelae when given to those at risk of
developing HUS after the onset of bloody diarrhea. Targeting the
two toxins for neutralization seems an obvious approach, and
their interception is more likely to be effective in the circulation
than in the lumen of the large bowel, where they are liberated
by the bacteria. With this in mind, we developed HuMAbs to
neutralize Stx (17–19), which were shown to be highly effective in
protecting STEC-infected piglets (17, 20, 21). Other investigators
have also developed Stx-neutralizing chimeric (47) or humanized
(48, 49) MAbs. HuMAb 5C12, specific for Stx2, was found to be
highly effective in protecting piglets 48 h after STEC infection; a
dose of 0.4 mg/kg of body weight protected 80% of piglets (20).
This product is slowly making its way through to a phase I clinical
trial with human volunteers (unpublished data). However, HuMAb
production and delivery to individuals at risk are expected to be very
costly, requiring intravenous administration; thus, they may be of-
fered only to patients presenting with HUS, at which point it may be
too late for a complete recovery. Hence, our group continued the
search for a treatment that is easy tomanufacture at a lowcost, simple
to administer by i.m. injection, and safe and that can be given to all
individuals at risk who either present with diarrhea, have been ex-
posed toaknownsourceof infection,or showsymptomsofHUS.We
believe that treatment with a product such as the Ad/VNA-Stx de-
scribed in this paper could provide these benefits.
The outcome of the experiments in the pigletmodel is compel-
ling evidence of the efficacy of this therapeutic approach to a very
serious disease against which there is currently no specific treat-
ment or prevention. These experiments show that a single i.m.
injection of an Ad vector-delivered VNA-Stx gene, given before
challenge with STEC, fully protected piglets against fatal systemic
intoxication, in contrast with a placebo Ad vector. More signifi-
cant, however, is the demonstration that a single i.m. injection of
Ad/VNA-Stx, given 24 h after bacterial challenge, protected 9 of 10
animals. Treatment at 48 h after bacterial challenge, shortly before
the onset of systemic intoxication, resulted in the survival of more
than half of the VNA-treated animals. This corresponds to the
TABLE 3 Survival of piglets orally challenged with 1010 CFU of STEC 86-24 followed by intramuscular administration of either a placebo or an
Stx2-neutralizing VNA treatment 24 h or 48 h later
Treatment (h post-STEC
challenge) Dose (vp/kg)
No. of
piglets
No. of surviving
piglets (% survival)a
Mean time (days) to
death/euthanasia (
 SD)b
Mean serum VNA concn
(g/ml) (range)c
Placebod (24) 1 1011 or 1 1012 6 0 (0) 3.50 (
0.54) A Not relevante
Ad/VNA-Stx (24) 1 1012 4 3 (75) 5.0 BC 0.70 (0.2–2.0)
1 1011 6 6 (100) 9.0 (
0.0) BC 0.08 (0.03–1.0)
Ad/VNA-Stx (48) 1 1012 7 4 (57) 3.33 (
0.57) AC 0.23 (0.05–0.4)
1 1011 2 1 (50) 3.0 AC 0.15
a Piglets that did not survive either died overnight or were euthanized due to severe illness.
b Surviving piglets in the Ad/VNA-Stx groups were euthanized after 9 days. The survival times of piglets that either were euthanized or died in Ad/VNA-Stx groups are shown.
Survival times followed by the same capital letter are not statistically significantly different. Different capital letters following survival times indicate statistically significant
differences (P 0.05).
c Estimated concentration of VNA in piglet serum at the time of euthanasia.
d Four piglets in the placebo group received 1012 vp of Ad/VNA-BoNTA/kg, and two received 1011 vp of Ad/VNA-Tcd/kg.
e The estimated mean VNA concentration in the sera of pigs receiving 1012 vp of Ad/VNA-BoNTA/kg was 3.75 g/ml, and that for pigs receiving 1011 vp of Ad/VNA-Tcd/kg was
0.02 g/ml.
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treatment of children just before the onset of HUS. Given the
hyperacute nature of HUS, protection is critical over a relatively
short period of 4 to 10 days after the onset of diarrhea or exposure
to STEC, which makes the half-life of the VNA in the circulation
less critical. VNA is also a one-time treatment, and therefore, there
should be no concern associated with possible VNA immunoge-
nicity from multiple dosing.
For this work, we employed a standard Ad5 vector at doses of
1011 to 1012 vp/kg, based on prior literature and experience. We
observed no significant difference in efficacy between the two
doses, so additional studies are required to establish the minimal
effective dose, as it relates to the time of delivery after bacterial
challenge. It is more than likely that the earlier the time of delivery
to an infected individual, the smaller the dose required for full
protection. For ultimate clinical use, it will likely be necessary to
develop novel nonreplicating Ad vectors specifically designed for
therapeutic expression of VNAs in patient serum. Such vectors
might be targeted to the vascular endothelium for optimal secre-
tion. Additionally, it may be advantageous to engineer the regu-
lated expression of the VNA such that expression can be induced
or repressed as needed for optimal efficacy, and to further reduce
the risk of developing neutralizing Abs to the VNA, which is al-
ready expected to be poorly immunogenic (50, 51). Finally, it may
be beneficial for the Ad vector to coexpress an anti-tag effector
antibody, since this would increase the potency of the epitopically
taggedVNAandpromotemore rapid clearance of the Shiga toxins
from the system (22, 23, 26).
As expected, the systemic production of VNA-Stx, which tar-
gets the toxins in the circulation, had no effect on the extent and
duration of diarrhea in piglets due to STEC infection. We made
the same observation with HuMAb treatment of STEC-infected
piglets (17, 20, 21). However, this treatment is intended to protect
against or treat HUS, and not the diarrhea due to STEC, which in
itself is less life-threating.
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